enGene Holdings changes name to enGene Therapeutics Inc., signals commercial readiness for detalimogene

enGene Therapeutics Inc.

Name change to enGene Therapeutics Inc. effective April 8, 2026; tickers ENGN/ENGNW unchanged.
BLA submission for detalimogene planned for 2H 2026 in BCG-unresponsive NMIBC with CIS.
Potential approval and commercial launch targeted for 2027.
New CUSIP numbers: common shares 29286X101, warrants 29286X119.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

enGene Therapeutics Inc.: Amended Articles to change corporate name from enGene Holdings Inc. to enGene Therapeutics Inc (effective 2026-04-08).

Change: charter amendment
Effective: 2026-04-08

Exact text from the filing

On April 6, 2026, enGene Therapeutics Inc., formerly known as enGene Holdings Inc. (the “Company”), filed a notice of alteration (the “Notice of Alteration”) with the Province of British Columbia Registrar of Companies to change the Company’s corporate name to enGene Therapeutics Inc., effective as of April 8, 2026 (the “Name Change”).

View on SEC.gov

101 governance changes filed in the last 30 days. Browse all governance changes →

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-149597

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.